Gain Therapeutics (NASDAQ:GANX – Get Free Report) released its earnings results on Tuesday. The company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.13) by $0.06, Zacks reports.
Gain Therapeutics Stock Performance
NASDAQ:GANX traded up $0.04 during trading hours on Tuesday, reaching $1.12. The stock had a trading volume of 147,911 shares, compared to its average volume of 710,129. The stock has a 50 day simple moving average of $1.52 and a 200 day simple moving average of $1.83. The stock has a market cap of $49.09 million, a P/E ratio of -2.25 and a beta of 0.29. Gain Therapeutics has a 12-month low of $0.94 and a 12-month high of $4.34. The company has a debt-to-equity ratio of 0.02, a quick ratio of 4.36 and a current ratio of 4.36.
Wall Street Analysts Forecast Growth
A number of equities analysts recently weighed in on GANX shares. Weiss Ratings reissued a “sell (e+)” rating on shares of Gain Therapeutics in a research note on Friday, September 4th. BTIG Research restated a “buy” rating and set a $5.00 price objective on shares of Gain Therapeutics in a report on Monday, October 5th. Finally, HC Wainwright reiterated a “buy” rating and issued a $8.00 price target on shares of Gain Therapeutics in a research note on Monday, October 5th. Four research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $7.67.
Get Our Latest Research Report on Gain Therapeutics
Gain Therapeutics Company Profile
Gain Therapeutics, Inc is a biotechnology company focused on developing small-molecule therapies for diseases associated with lysosomal dysfunction, including neurodegenerative and rare disorders. The company’s approach is designed to identify compounds that bind to and modulate disease-related proteins, with the goal of restoring their function and addressing underlying disease mechanisms.
Gain Therapeutics’ lead investigational program, GT-02287, is an orally administered, brain-penetrant small molecule being developed for GBA1-associated Parkinson’s disease.
See Also
- Five stocks we like better than Gain Therapeutics
- DraftKings Just Lost 20%—And Its Biggest Gamble Is Still Ahead
- Barrick’s Earnings Beat Could Be Overshadowed by an Even Bigger Opportunity
- Axon vs. Motorola: Which Public Safety Stock Has More Upside After Q3 Earnings?
- Wall Street May Be Making a Big Mistake With monday.com Stock
Receive News & Ratings for Gain Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gain Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
